Federal Register / Vol. 83, No. 129 / Thursday, July 5, 2018 / Notices 31421 

If additional information is required 

contact: Melody Braswell, Department 

Clearance Officer, United States 

Department of Justice, Justice 

Management Division, Policy and 

Planning Staff, Two Constitution 

Square, 145 N Street NE, 3E.405A, 

Washington, DC 20530. 

Dated: June 29, 2018. 

Melody Braswell, 

Department Clearance Officer for PRA, U.S. 

Department of Justice. 

[FR Doc. 2018–14413 Filed 7–3–18; 8:45 am] 

BILLING CODE 4410–14–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Importer of Controlled Substances 

Application: S & B Pharma, Inc. 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before August 6, 2018. Such persons 

may also file a written request for a 

hearing on the application on or before 

August 6, 2018. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DRW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for hearing must be 

sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All requests for hearing 

should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/LJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DRW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Assistant 

Administrator of the DEA Diversion 

Control Division (‘‘Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.34(a), this is notice that on June 6, 

2018, S & B Pharma, Inc. DBA NORAC 

Pharma, 405 S Motor Avenue, Azusa, 

California 91702 applied to be registered 

as an importer of the following basic 

classes of controlled substances: 

Controlled substance Drug code Schedule 

4-Anilino-N-phenethyl-4-piperidine (ANPP) ............................................................................................................. 8333 II 

Tapentadol ............................................................................................................................................................... 9780 II 

The company plans to import the 

controlled substances in bulk for the 

manufacture of other controlled 

substances for its customers. Tapentadol 

(9780) will be imported in Intermediate 

form to bulk manufacture Tapentadol 

for distribution to its customers. No 

other activity for these drug codes will 

be allowed. 

Dated: June 26, 2018. 

John J. Martin, 

Assistant Administrator. 

[FR Doc. 2018–14396 Filed 7–3–18; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF LABOR 

Office of the Secretary 

Agency Information Collection 

Activities; Submission for OMB 

Review; Comment Request; Methylene 

Chloride Standard 

ACTION: Notice of availability; request 

for comments. 

SUMMARY: The Department of Labor 

(DOL) is submitting the Occupational 

Safety and Health Administration 

(OSHA) sponsored information 

collection request (ICR) titled, 

‘‘Methylene Chloride Standard,’’ to the 

Office of Management and Budget 

(OMB) for review and approval for 

continued use, without change, in 

accordance with the Paperwork 

Reduction Act of 1995 (PRA). Public 

comments on the ICR are invited. 

DATES: The OMB will consider all 

written comments that agency receives 

on or before August 6, 2018. 

ADDRESSES: A copy of this ICR with 

applicable supporting documentation; 

including a description of the likely 

respondents, proposed frequency of 

response, and estimated total burden 

may be obtained free of charge from the 

RegInfo.gov website at http://

www.reginfo.gov/public/do/PRA

ViewICR?ref_nbr=201805-1218-003 or 

by contacting Michel Smyth by 

telephone at 202–693–4129, TTY 202– 

693–8064, (these are not toll-free 

numbers) or by email at DOL_PRA_

PUBLIC@dol.gov. 

Submit comments about this request 

by mail to the Office of Information and 

Regulatory Affairs, Attn: OMB Desk 

Officer for DOL–OSHA, Office of 

Management and Budget, Room 10235, 

725 17th Street NW, Washington, DC 

20503; by Fax: 202–395–5806 (this is 

not a toll-free number); or by email: 

OIRA_submission@omb.eop.gov. 

Commenters are encouraged, but not 

required, to send a courtesy copy of any 

comments by mail or courier to the U.S. 

Department of Labor-OASAM, Office of 

the Chief Information Officer, Attn: 

Departmental Information Compliance 

Management Program, Room N1301, 

200 Constitution Avenue NW, 

Washington, DC 20210; or by email: 

DOL_PRA_PUBLIC@dol.gov. 

FOR FURTHER INFORMATION CONTACT: 

Michel Smyth by telephone at 202–693– 

4129, TTY 202–693–8064, (these are not 

toll-free numbers) or by email at DOL_

PRA_PUBLIC@dol.gov. 

SUPPLEMENTARY INFORMATION: This ICR 

seeks to extend PRA authority for the 

Methylene Chloride Standard 

information collection codified in 

regulations 29 CFR 1910–1052. The 

purpose of the Standard and its 

information collection requirements is 

to protect workers from the adverse 

health effects that may result from their 

exposure to MC. The requirements in 

the Standard include: Worker exposure 

monitoring, notifying workers of their 

MC exposures, administering medical 

examinations to workers, providing 

examining physicians with specific 

program and worker information, 

ensuring that workers receive a copy of 

their medical examination results, 

maintaining workers’ exposure 

monitoring and medical examination 

records for specific periods, and 


amozie on DSK3GDR082PROD with NOTICES1